Santhera Pharmaceuticals Holding AG · SIX:SANN

Santhera Pharmaceuticals — Shareholder Meeting (April 2010)

19 slides from Santhera Pharmaceuticals's shareholder meeting presentation, Apr 26, 2010

  1. Slide 1: Building the Company on Two Pillars for Growth

    Building the Company on Two Pillars for Growth 2010 Annual Shareholders’ Meeting Basel, April 26, 2010

  2. Slide 2: Today's Agenda

    Today’s Agenda 1. Key Achievements 2009 2. Sales of Catena® 3. Update on Clinical Development Programs 4. Financial Results 2009 2010 Annual Shareholders’ Meeting, April 26, 2010 2

  3. Slide 3: Key Achievements in 2009

    Key Achievements in 2009 ƒ CHF 22.3m revenues from product sales and partnering Cash flow break-even 2H 2009 Financed beyond 2011 ƒ Clinical development of Catena®/Sovrima® in Friedreich’s Ataxia almost completed ƒ Phase III study with Catena®/Sovrima® initiated in Duchenne Muscular Dystrophy ƒ Fipa

  4. Slide 4: Today's Agenda

    Today’s Agenda 1. Key Achievements 2009 2. Sales of Catena® 3. Update on Clinical Development Programs 4. Financial Results 2009 2010 Annual Shareholders’ Meeting, April 26, 2010 4

  5. Slide 5: Catena in Canada: Driven by Strong Demand from Medical Community

    Catena® in Canada: Driven by Strong Demand from Medical Community Patient numbers (cumulative) 160 140 120 100 80 60 40 20 0 Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar 08 09 10 Total patients on prescription Total insurance approved 2010 Annual Shareholders’ Meeting, Apr

  6. Slide 6: Canadian Sales Figures Underlines Commercial Success of Catena

    Canadian Sales Figures Underlines Commercial Success of Catena® Net sales (CHF, cumulative) 2,500,000 2,000,000 ƒ CHF 1.6m net sales in FY2009 1,500,000 1,000,000 500,000 0 Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar 08 09 10 2010 Annual Shareholders’ Meeting, April 26, 2010

  7. Slide 7: Catena in NPP: Responding to Patient Requests from Europe

    Catena® in NPP: Responding to Patient Requests from Europe Gross sales (CHF, cumulative) 500,000 400,000 300,000 200,000 100,000 0 Sep 09 Oct Nov Dec Jan 10 Feb Mar 2010 Annual Shareholders’ Meeting, April 26, 2010 7

  8. Slide 8: Analysis of ICARS Responders Indicate Patients Benefit from Catena

    Analysis of ICARS Responders Indicate Patients Benefit from Catena® ƒ Comparable % of responders on Catena® with clinically meaningful improvement (2.5 points and 5 points on ICARS) in IONIA & NICOSIA studies Improvement of >2.5 points on ICARS Improvement of ≥5 points on ICARS 70 45 40 60 35 % Resp

  9. Slide 9: Real-life Testimonials Support Efficacy of Catena Observed in Clinical Studies

    Real-life Testimonials Support Efficacy of Catena® Observed in Clinical Studies Without the drug my speech I am confident enough to engage in would be incomprehensible and I conversations again, and I am able to would lose my job as receptionist write again by hand (Fabienne, 35) (Nadine, 28) I walk

  10. Slide 10: Today's Agenda

    Today’s Agenda 1. Key Achievements 2009 2. Sales of Catena® 3. Update on Clinical Development Programs 4. Financial Results 2009 2010 Annual Shareholders’ Meeting, April 26, 2010 10

  11. Slide 11: Product Portfolio Focused on Orphan Neuromuscular Indications

    Product Portfolio Focused on Orphan Neuromuscular Indications Preclinical Phase I Phase II Phase III Filing Market Catena® in Canada Friedreich’s Ataxia Catena® / Sovrima® Friedreich’s Ataxia Catena® / Sovrima® Duchenne Muscular Dystrophy Catena® Leber’s Hereditary Optic Neuropathy Catena® MELAS Syn

  12. Slide 12: Advances in Clinical Pipeline (1): Catena/Sovrima

    Advances in Clinical Pipeline (1): Catena®/Sovrima® 2009 2010 Friedreich‘s Ataxia: MICONOS Phase III study Results Filing Leber‘s Hereditary Optic Neuropathy: RHODOS Phase II study Results Filing? MELAS: MELTIMI Phase II study (Columbia University) Results Duchenne Muscular Dystrophy: DELOS Phase II

  13. Slide 13: Levodopa-Induced Dyskinesia in Parkinson's Disease

    Levodopa-Induced Dyskinesia in Parkinson’s Disease 2010 Annual Shareholders’ Meeting, April 26, 2010 Source: YouTube.com 13

  14. Slide 14: Fipamezole Shows Dose-Proportionality in Reducing Dyskinesia

    Fipamezole Shows Dose-Proportionality in Reducing Dyskinesia (Assessed by LIDS) Change: D28-BL; ITT-OC 0 1 2 3 4 LIDS Placebo 30 mg 60 mg 90 mg -1 LIDS points P-value* - 0.790 0.521 0.047 LIDS P-value -2 Linear regression model 0.0187 Jonckheere‘s test for group 0.014 -3 * RMANCOVA analysis comparis

  15. Slide 15: Partnering Fipamezole for Development & Commercialization

    Partnering Fipamezole for Development & Commercialization ƒ Licensing agreement with Biovail signed in August 2009 ̶ Development and commercialization in US and Canada ̶ Initiation of Phase III in 2011 ̶ USD 12m upfront payment ̶ Up to USD 35m development/regulatory and up to USD 145m sales mileston

  16. Slide 16: Today's Agenda

    Today’s Agenda 1. Key Achievements 2009 2. Sales of Catena® 3. Update on Clinical Development Programs 4. Financial Results 2009 2010 Annual Shareholders’ Meeting, April 26, 2010 16

  17. Slide 17: Financial Information 2009

    Financial Information 2009 Key Financials (IFRS, consolidated, in CHF thousands) 2009 2008 Cash and cash equivalents 53,320 75,006 Net decrease in cash and cash equivalents –21,686 –31,612 Total revenues 22,339 48 Total operating expenses –48,544 –45,642 - whereof R&D –31,536 –31,467 - whereof M&S –

  18. Slide 18: Share Price Development in 2009

    Share Price Development in 2009 IONIA results 52.40 SPI SBIOM SLIFE 40.00 25.70 SANN 25.35 23.50 FJORD results DELOS start 20.25 Biovail deal 2010 Annual Shareholders’ Meeting, April 26, 2010 18

  19. Slide 19: Upcoming Financial Calendar: Annual Results and Shareholders' Meeting

    2010 FY 2008 Annual Results, Shareholders’ February 27, Meeting, 2009 April 26, 2010 19

Santhera Pharmaceuticals — Shareholder Meeting (April 2010) on 6ix